APA (7th ed.) Citation

Kloka, J., Friedrichson, B., Dauth, S., Foldenauer, A. C., Bulczak-Schadendorf, A., Vehreschild, M. J. G. T., . . . Grebe, L. (2022). Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients — the randomized, EU-wide, placebo-controlled, phase II study design of IXION. Trials, 23(1), 1. https://doi.org/10.1186/s13063-022-06609-x

Chicago Style (17th ed.) Citation

Kloka, Jan, et al. "Potential of FX06 to Prevent Disease Progression in Hospitalized Non-intubated COVID-19 Patients — the Randomized, EU-wide, Placebo-controlled, Phase II Study Design of IXION." Trials 23, no. 1 (2022): 1. https://doi.org/10.1186/s13063-022-06609-x.

MLA (9th ed.) Citation

Kloka, Jan, et al. "Potential of FX06 to Prevent Disease Progression in Hospitalized Non-intubated COVID-19 Patients — the Randomized, EU-wide, Placebo-controlled, Phase II Study Design of IXION." Trials, vol. 23, no. 1, 2022, p. 1, https://doi.org/10.1186/s13063-022-06609-x.